Coya Therapeutics, Inc.

Coya Therapeutics, Inc. announced its Annual Meeting of Stockholders will be held virtually on June 25, 2026, at 12:00 p.m. Central Time. Stockholders will vote on the election of two Class I director nominees, Wilbur Ross and Dieter Weinand, to serve until the 2029 annual meeting. Additionally, stockholders will ratify the appointment of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date for voting is May 1, 2026.

Coya Therapeutics, Inc. has entered into a Sales Agreement with Leerink Partners LLC to offer and sell shares of its common stock for aggregate gross proceeds of up to $30,000,000. The sales will be conducted through "at the market" equity offerings on the Nasdaq Capital Market. The company will pay Leerink Partners a 3.0% commission on the gross proceeds from any shares sold.

Coya Therapeutics reported a net loss of $(7.21) million for Q1 2026, an improvement from $(7.31) million in Q1 2025, with net loss per share improving to $(0.32) from $(0.44). Collaboration revenue remained stable at $0.25 million. The company's cash and cash equivalents increased to $50.7 million as of March 31, 2026, primarily due to a $11.1 million private placement in January 2026. Coya expects its current cash to fund operations for at least one year, despite an accumulated deficit of $69.2 million.